3RDEYEBIO
LIVE

Serial Number

90285221

Owner

3RDEYEBIO LLC

Attorney

Maha Jafarey

First Use Date

Mar 1, 2020

Filing Date

Oct 28, 2020

Add to watchlist:

No watchlists yet
View on USPTO

3RDEYEBIO Trademark

Serial Number: 90285221 • Registration: 6675094

3RDEYEBIO is a trademark filed by 3RDEYEBIO LLC on October 28, 2020. The trademark is classified under Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

3RDEYEBIO LLC (2 trademarks)

3554 NE 85th St. Suite A
Seattle, WA 98115

Entity Type: 16

Trademark Details

Filing Date

October 28, 2020

Registration Date

March 22, 2022

First Use Anywhere

March 1, 2020

First Use in Commerce

March 1, 2020

Published for Opposition

January 4, 2022

Goods & Services

Investor development and management in the nature of business intermediary services relating to the matching of potential private investors with entrepreneurs needing funding; Advisory board development and management being personnel management services; Regulatory compliance development and management in the nature of regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies

Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Biochemical research and development; Conducting clinical trials for others; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenomics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical research services in the field of cancer; Pharmaceutical research and development; Providing a web site featuring technology enabling physicians to access resources in clinical medicine; Providing a website featuring educational information in the field of clinical research; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research and development; Scientific and technological services, namely, research and design in the field of integrated system architecture that allows for the rapid development of highly interactive and customizable learning application; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and acute and chronic devastating diseases and conditions beyond cancer, stem cell research services; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Filing History

REGISTERED-PRINCIPAL REGISTER
Mar 22, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 4, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 4, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 15, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 1, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 1, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 1, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 1, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 1, 2021 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 1, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 1, 2021 GNSL
SUSPENSION LETTER WRITTEN
Jul 1, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 1, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 1, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 3, 2021 GNRN
NON-FINAL ACTION E-MAILED
Apr 3, 2021 GNRT
NON-FINAL ACTION WRITTEN
Apr 3, 2021 CNRT
ASSIGNED TO EXAMINER
Mar 29, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 20, 2020 NWOS
NEW APPLICATION ENTERED
Nov 1, 2020 NWAP